Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab
NIOSH released its 2024 list of hazardous drugs, adding liraglutide and pertuzumab. Med-spas using these drugs must update handling protocols to protect staff from occupational exposure.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Med-spas and aesthetics clinics that handle liraglutide (e.g., for weight loss) or pertuzumab (not common in aesthetics, but relevant if used off-label). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; OSHA may cite under the General Duty Clause if not addressed.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Liraglutide and pertuzumab are now classified as hazardous drugs, requiring adherence to NIOSH safe handling guidelines (e.g., engineering controls, PPE, training).
Who it affects
Med-spas and aesthetics clinics that handle liraglutide (e.g., for weight loss) or pertuzumab (not common in aesthetics, but relevant if used off-label).
What you must do
Update your facility's hazardous drug list, implement safe handling procedures, and train staff on new protocols.
Deadline
Immediately; OSHA may cite under the General Duty Clause if not addressed.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial